Case 3: NIVOLUMAB, an anti-PD1 checkpoint inhibitor in lung adenocarcinoma. A case report

Date 05 February 2016
Event ESMO Preceptorship on Lung Cancer Manchester 2016
Session Locally advanced NSCLC
Topics Cytotoxic agents
Non-small-cell lung cancer
Therapy
Biological therapy
Presenter Giulia Buzzatti